Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: A single-centre experience

Bone Marrow Transplantation

Volumn 45, Issue 10, 2010, Pages 1502-1507

  Krishnamurthy, P ^a   Lim, Z Y ^a,b   Nagi, W ^a   Kenyon, M ^a   Mijovic, A ^a   Ireland, R ^a   Marsh, J ^a   Ho, A Y L ^a   Mufti, G J ^a,b   Pagliuca, A ^a,b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

allogeneic; CMML; reduced intensity conditioning; T cell depletion

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHIMERA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; TREATMENT OUTCOME;

ADULT; BONE MARROW CELLS; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; GREAT BRITAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957949202     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.375     Document Type: Article

References (12)

1. Jaffe EHN, Stein H, Vardiman JW. World Health Organisation classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe EHN, Stein H, Vardiman JW (eds). IARC Press: Lyon, France, 2001.
2. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukaemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
3. Benesch M, Deeg J. Haemopoietic cell transplantation for adult patients with myelodysplastic syndromes and myelopro-liferative disorders. Mayo Clin Proc 2003; 78: 981-990.
4. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A et al. Allogeneic stem cell transplantation of adult CMML: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67-73.
5. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) condition-ing. Blood 2004; 104: 1616-1623.
6. Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br JHaematol 2006; 135: 201-209.
7. Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haemato-poeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007; 138: 517-526.
8. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
9. Sullivan KM. Graft versus host disease. In: Thomas ED, Blume KG, Forman SJ, (eds). Hematopoietic Cell Transplanta-tion. Blackwell Sciences: Malden, MA, 1999, 515-536.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
11. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukaemia. Bone Marrow Transplant 2006; 37: 1003-1008.
12. Ocheni S, Kroger N, Zabelina T, Zander AR, Bacher U. Outome of allo-SCT for chronic myelomonocytic leukaemia. Bone Marrow Transplant 2009; 43: 659-661.